MA45069A - Protéines agonistes du récepteur trail monocaténaires - Google Patents
Protéines agonistes du récepteur trail monocaténairesInfo
- Publication number
- MA45069A MA45069A MA045069A MA45069A MA45069A MA 45069 A MA45069 A MA 45069A MA 045069 A MA045069 A MA 045069A MA 45069 A MA45069 A MA 45069A MA 45069 A MA45069 A MA 45069A
- Authority
- MA
- Morocco
- Prior art keywords
- catenary
- agonist proteins
- trail
- receiver agonist
- trail receiver
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461983152P | 2014-04-23 | 2014-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45069A true MA45069A (fr) | 2019-04-03 |
Family
ID=53055121
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA039770A MA39770A (fr) | 2014-04-23 | 2015-04-23 | Protéines agonistes du récepteur trail monocaténaires |
| MA045069A MA45069A (fr) | 2014-04-23 | 2015-04-23 | Protéines agonistes du récepteur trail monocaténaires |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA039770A MA39770A (fr) | 2014-04-23 | 2015-04-23 | Protéines agonistes du récepteur trail monocaténaires |
Country Status (37)
| Country | Link |
|---|---|
| US (4) | US9908927B2 (fr) |
| EP (2) | EP3134430B1 (fr) |
| JP (2) | JP6523331B2 (fr) |
| KR (2) | KR102079919B1 (fr) |
| CN (2) | CN106459221B (fr) |
| AR (1) | AR100168A1 (fr) |
| AU (3) | AU2015249649B2 (fr) |
| BR (1) | BR112016024515B1 (fr) |
| CA (2) | CA3184067A1 (fr) |
| CL (1) | CL2016002683A1 (fr) |
| CR (1) | CR20160516A (fr) |
| CY (1) | CY1120281T1 (fr) |
| DK (1) | DK3134430T3 (fr) |
| DO (1) | DOP2016000284A (fr) |
| EC (1) | ECSP16089579A (fr) |
| ES (1) | ES2672368T3 (fr) |
| HR (1) | HRP20180950T1 (fr) |
| HU (1) | HUE038914T2 (fr) |
| IL (2) | IL248244B (fr) |
| LT (1) | LT3134430T (fr) |
| MA (2) | MA39770A (fr) |
| MX (2) | MX2016013858A (fr) |
| MY (1) | MY181986A (fr) |
| NO (1) | NO2776305T3 (fr) |
| PE (1) | PE20170299A1 (fr) |
| PH (1) | PH12016502079B1 (fr) |
| PL (1) | PL3134430T3 (fr) |
| PT (1) | PT3134430T (fr) |
| RS (1) | RS57153B1 (fr) |
| RU (1) | RU2699285C2 (fr) |
| SG (3) | SG10201806465TA (fr) |
| SI (1) | SI3134430T1 (fr) |
| TR (1) | TR201806912T4 (fr) |
| TW (2) | TWI747178B (fr) |
| UA (1) | UA118286C2 (fr) |
| UY (1) | UY36095A (fr) |
| WO (1) | WO2015164588A1 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107709355B (zh) * | 2015-05-04 | 2021-09-14 | 阿珀吉尼科斯股份公司 | 单链cd40受体激动剂蛋白 |
| AU2016342420B2 (en) * | 2015-10-23 | 2020-10-01 | Apogenix Ag | Single-chain LIGHT receptor agonist proteins |
| AU2016341402B2 (en) * | 2015-10-23 | 2020-08-27 | Apogenix Ag | Single-chain GITR-receptor agonist proteins |
| AU2016341409B2 (en) | 2015-10-23 | 2021-02-25 | Apogenix Ag | Single-chain CD27-receptor agonist proteins |
| WO2017102010A1 (fr) * | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Nouvelles protéines de fusion à cytokine |
| CN109153711B (zh) * | 2016-03-01 | 2022-04-26 | 伊利诺伊大学理事会 | 具有降低的l-谷氨酰胺酶活性和增强的稳定性的l-天冬酰胺酶变体和融合蛋白 |
| MX2018011219A (es) * | 2016-03-16 | 2019-01-10 | Merrimack Pharmaceuticals Inc | Trail diseñado por ingenieria para terapia de cancer. |
| US10501744B2 (en) | 2016-05-04 | 2019-12-10 | Indiana University Research And Technology Corporation | Presentation of bioactive proteins |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| CN109641033A (zh) * | 2016-06-13 | 2019-04-16 | 梅里麦克制药股份有限公司 | 用基于trail的治疗剂或死亡受体激动剂选择和治疗患者的方法 |
| EP3360898A1 (fr) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Molécules bispécifiques présentant une immunoréactivité par rapport à tnf-related apoptosis-inducing ligand receptor 2 et à cadherin 17 pour le traitement du cancer |
| CA3106549A1 (fr) * | 2017-08-11 | 2019-02-14 | The Board Of Trustees Of The University Of Illinois | Variantes tronquees de la l-asparaginase de cochon d'inde et procedes d'utilisation |
| WO2019178438A1 (fr) | 2018-03-15 | 2019-09-19 | Abbvie Inc. | Abbv-621 en combinaison avec des agents anticancéreux pour le traitement du cancer |
| WO2019178433A1 (fr) | 2018-03-15 | 2019-09-19 | Abbvie Inc. | Abbv-621 en association avec des agents anticancéreux pour le traitement du cancer du pancréas |
| EP4149964A2 (fr) | 2020-05-15 | 2023-03-22 | Apogenix AG | Modulateurs immunitaires multi-spécifiques |
| WO2022248662A1 (fr) | 2021-05-28 | 2022-12-01 | Julius-Maximilians-Universität Würzburg | Molécules de liaison protéiques recombinantes |
| WO2023088876A1 (fr) | 2021-11-16 | 2023-05-25 | Apogenix Ag | Modulateurs immunitaires multi-spécifiques |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7645700A (en) | 1999-10-07 | 2001-05-10 | Maxygen Aps | Single-chain antagonist polypeptides |
| DE19963859A1 (de) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
| CA2314199A1 (fr) | 2000-07-21 | 2002-01-21 | Robert Simoneau | Puce c |
| MXPA03005036A (es) | 2000-12-07 | 2003-09-05 | Lilly Co Eli | Proteinas de fusion glp-1. |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7538088B2 (en) | 2002-04-26 | 2009-05-26 | California Institute Of Technology | Method for inhibiting angiogenesis by administration of the extracellular domain of D1-1 polypeptide |
| DE102004014983A1 (de) | 2004-03-26 | 2005-10-20 | Univ Stuttgart | Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung |
| US20060188498A1 (en) * | 2005-02-18 | 2006-08-24 | Genentech, Inc. | Methods of using death receptor agonists and EGFR inhibitors |
| US8388962B2 (en) * | 2005-04-15 | 2013-03-05 | Rappaport Family Institute For Research In The Medical Sciences | Molecules and methods of using same for treating MCP-1/CCR2 associated diseases |
| CA2606102C (fr) | 2005-04-26 | 2014-09-30 | Medimmune, Inc. | Modulation de la fonction d'effecteur d'anticorps par ingenierie de domaine "charniere" |
| EP1894940A1 (fr) | 2006-08-28 | 2008-03-05 | Apogenix GmbH | Protéines de fusion de la superfamille TNF |
| EP2176288B1 (fr) | 2007-07-10 | 2015-11-04 | Apogenix GmbH | Protéines de fusion collectines de la superfamille des tnf |
| BRPI0913406A2 (pt) | 2008-06-03 | 2018-01-09 | Abbott Lab | imunoglobulinas de domínio variável duplo e usos das mesmas |
| EP2310509B1 (fr) * | 2008-07-21 | 2015-01-21 | Apogenix GmbH | Molécules à une seule chaîne |
| US20110287001A1 (en) | 2008-09-22 | 2011-11-24 | Tetralogic Pharmaceuticals | Method of treatment |
| EP2379585A2 (fr) * | 2008-10-10 | 2011-10-26 | Anaphore, Inc. | Polypeptides qui se lient à trail-ri et trail-r2 |
| ES2593049T3 (es) | 2009-01-09 | 2016-12-05 | Apogenix Ag | Proteínas de fusión que forman trímeros |
| CA2750533A1 (fr) * | 2009-01-23 | 2010-07-29 | Biogen Idec Ma Inc. | Polypeptides fc stabilises avec une fonction effectrice reduite et procedes d'utilisation |
| EP2516458A1 (fr) | 2009-12-22 | 2012-10-31 | Novartis AG | Protéine hybride tétravalente à région constante d'anticorps anti-cd-47 à utiliser en thérapie |
| CA2795325A1 (fr) * | 2010-04-13 | 2011-10-20 | Medimmune, Llc | Echafaudages multimeriques a base de domaine de fibronectine de type iii |
| US9764038B2 (en) * | 2011-12-23 | 2017-09-19 | Innate Pharma | Enzymatic conjugation of antibodies |
| CN104640876A (zh) * | 2012-07-18 | 2015-05-20 | 阿珀吉尼科斯有限公司 | 包含CD95-Fc同种型的混合物的组合物 |
-
2012
- 2012-11-06 NO NO12790406A patent/NO2776305T3/no unknown
-
2015
- 2015-04-23 SG SG10201806465TA patent/SG10201806465TA/en unknown
- 2015-04-23 MA MA039770A patent/MA39770A/fr unknown
- 2015-04-23 AR ARP150101224A patent/AR100168A1/es active IP Right Grant
- 2015-04-23 KR KR1020167032819A patent/KR102079919B1/ko active IP Right Grant
- 2015-04-23 TW TW109106778A patent/TWI747178B/zh active
- 2015-04-23 PE PE2016002016A patent/PE20170299A1/es unknown
- 2015-04-23 SI SI201530223T patent/SI3134430T1/en unknown
- 2015-04-23 MA MA045069A patent/MA45069A/fr unknown
- 2015-04-23 CR CR20160516A patent/CR20160516A/es unknown
- 2015-04-23 RU RU2016145608A patent/RU2699285C2/ru active
- 2015-04-23 SG SG11201608767XA patent/SG11201608767XA/en unknown
- 2015-04-23 EP EP15721089.9A patent/EP3134430B1/fr active Active
- 2015-04-23 WO PCT/US2015/027270 patent/WO2015164588A1/fr active Application Filing
- 2015-04-23 TR TR2018/06912T patent/TR201806912T4/tr unknown
- 2015-04-23 DK DK15721089.9T patent/DK3134430T3/en active
- 2015-04-23 MX MX2016013858A patent/MX2016013858A/es active IP Right Grant
- 2015-04-23 ES ES15721089.9T patent/ES2672368T3/es active Active
- 2015-04-23 EP EP18155146.6A patent/EP3366699A1/fr not_active Withdrawn
- 2015-04-23 CA CA3184067A patent/CA3184067A1/fr active Pending
- 2015-04-23 BR BR112016024515-6A patent/BR112016024515B1/pt active IP Right Grant
- 2015-04-23 HU HUE15721089A patent/HUE038914T2/hu unknown
- 2015-04-23 JP JP2016564068A patent/JP6523331B2/ja active Active
- 2015-04-23 CN CN201580031858.7A patent/CN106459221B/zh active Active
- 2015-04-23 TW TW104113087A patent/TWI683825B/zh active
- 2015-04-23 AU AU2015249649A patent/AU2015249649B2/en active Active
- 2015-04-23 CA CA2946402A patent/CA2946402C/fr active Active
- 2015-04-23 PL PL15721089T patent/PL3134430T3/pl unknown
- 2015-04-23 UA UAA201611802A patent/UA118286C2/uk unknown
- 2015-04-23 UY UY0001036095A patent/UY36095A/es active IP Right Grant
- 2015-04-23 KR KR1020197035100A patent/KR20190135546A/ko not_active Application Discontinuation
- 2015-04-23 SG SG10202111785VA patent/SG10202111785VA/en unknown
- 2015-04-23 PT PT157210899T patent/PT3134430T/pt unknown
- 2015-04-23 LT LTEP15721089.9T patent/LT3134430T/lt unknown
- 2015-04-23 CN CN202010767219.XA patent/CN111718424A/zh active Pending
- 2015-04-23 RS RS20180450A patent/RS57153B1/sr unknown
- 2015-04-23 US US14/694,358 patent/US9908927B2/en active Active
- 2015-04-23 MY MYPI2016703814A patent/MY181986A/en unknown
-
2016
- 2016-10-07 IL IL248244A patent/IL248244B/en active IP Right Grant
- 2016-10-19 DO DO2016000284A patent/DOP2016000284A/es unknown
- 2016-10-19 PH PH12016502079A patent/PH12016502079B1/en unknown
- 2016-10-21 CL CL2016002683A patent/CL2016002683A1/es unknown
- 2016-10-21 MX MX2019013587A patent/MX2019013587A/es unknown
- 2016-11-23 EC ECIEPI201689579A patent/ECSP16089579A/es unknown
-
2018
- 2018-02-02 US US15/887,509 patent/US20180222962A1/en not_active Abandoned
- 2018-05-25 CY CY20181100568T patent/CY1120281T1/el unknown
- 2018-06-19 HR HRP20180950TT patent/HRP20180950T1/hr unknown
- 2018-11-30 AU AU2018271369A patent/AU2018271369B2/en active Active
-
2019
- 2019-04-24 JP JP2019082671A patent/JP6714751B2/ja active Active
-
2020
- 2020-02-11 IL IL272612A patent/IL272612A/en unknown
- 2020-03-30 AU AU2020202247A patent/AU2020202247A1/en not_active Abandoned
- 2020-08-14 US US16/993,569 patent/US20210040178A1/en not_active Abandoned
-
2023
- 2023-07-14 US US18/352,769 patent/US20240174731A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45069A (fr) | Protéines agonistes du récepteur trail monocaténaires | |
| DK3344654T3 (da) | Anti-lag-3-antistoffer | |
| DK3538864T3 (da) | Mikrotom | |
| DK3180363T3 (da) | Sirp-alpha-immunoglobulin fusionsproteiner | |
| DK3140653T3 (da) | Direkte immunhistokemianalyse | |
| DK3143037T3 (da) | Alpha4beta7-integrin-thioether-peptidantagonister | |
| DK3350218T3 (da) | Polyomavirus-neutraliserende antistoffer | |
| DK3107562T3 (da) | P97-ids-fusionsproteiner | |
| UA31494S (uk) | Холодильник | |
| DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
| DK3215530T3 (da) | Forbedrede il-6 antistoffer | |
| DK3099791T3 (da) | Protein | |
| DK3164410T3 (da) | Protein-indvinding | |
| DK3099793T3 (da) | Protein | |
| DK3224552T3 (da) | Køleapparat | |
| MA44599A (fr) | Récepteur volumétrique | |
| DK3310756T3 (da) | Thromboxanreceptorantagonister | |
| DK2955461T3 (da) | Forbedret solmodtagerkonfiguration | |
| FI10903U1 (fi) | Letkukela | |
| BR112016028429A2 (pt) | refrigerador | |
| ITUB20155682A1 (it) | Biella | |
| FI20145828A (fi) | Näytteenotin | |
| UA32617S (uk) | Кальян | |
| UA30829S (uk) | Кальян | |
| TH167737B (th) | เปปไทด์ในรูปออกซีโตซิน อะโกนิสท์ |